SEARCH

SEARCH BY CITATION

References

  • Agner K (1941). Verdoperoxidase. A ferment isolated from leukocytes. Acta Chem Scand A 2 (Suppl. 8): 162.
  • Andrews PC, Krinsky NI (1982). A kinetic analysis of the interaction of human myeloperoxidase with hydrogen peroxide, chloride ions, and protons. J Biol Chem 257: 1324013245.
  • Aratani Y, Koyama H, Nyui S, Suzuki K, Kura F, Maeda N (1999). Severe impairment in early host defense against Candida albicans in mice deficient in myeloperoxidase. Infect Immun 67: 18281836.
  • Arnhold J, Furtmüller PG, Regelsberger G, Obinger C (2001). Redox properties of the couple compound I/native enzyme of human myeloperoxidase and eosinophil peroxidase. Eur J Biochem 268: 51425148.
  • Arnhold J, Monzani E, Furtmüller PG, Zederbauer M, Casella L, Obinger C (2006). Kinetics and thermodynamics of halide and nitrite oxidation by mammalian peroxidases. Eur J Inorg Chem 19: 38013811.
  • Ator MA, David SK, Ortiz de Montellano PR (1987). Structure and catalytic mechanism of horseradish peroxidase. Regiospecific meso alkylation of the prosthetic heme group by alkylhydrazines. J Biol Chem 262: 1495414960.
  • Baldus S, Heeschen C, Meinertz T, Zeiher AM, Eiserich JP, Munzel T, et al., on behalf of the CAPTURE investigators (2003). Myeloperoxidase serum levels predict risk in patients with acute coronary syndromes. Circulation 108: 14401445.
  • Bandyopadhyay U, Bhattacharyya DK, Banerjee RK (1993). Mechanism-based inactivation of gastric peroxidase by mercaptomethylimidazole. Biochem J 296: 7984.
  • Bandyopadhyay U, Bhattacharyya DK, Chatterjee R, Banerjee RK (1995). Irreversible inactivation of lactoperoxidase by mercaptomethylimidazole through generation of a thiyl radical: its use to probe the active site. Biochem J 306: 751757.
  • Battistuzzi G, Bellei M, Zederbauer M, Furtmüller PG, Sola M, Obinger C (2006). Redox thermodynamics of the Fe(III)/Fe(II) couple of human myeloperoxidase in its high-spin and low-spin forms. Biochemistry 45: 1275012755.
  • Blair-Johnson M, Fiedler T, Fenna R (2001). Human myeloperoxidase: structure of a cyanide complex and its interaction with bromide and thiocyanate substrates at 1.9 Å resolution. Biochemistry 40: 1399013997.
  • Bos A, Wever R, Roos D (1978). Characterization and quantification of the peroxidase in human monocytes. Biochim Biophys Acta 525: 3744.
  • Bräsen JH, Hakkinen T, Malle E, Beisiegel U, Ylä-Herttuala S (2003). Patterns of oxidized epitopes, but not NF-kB expression, change during atherogenesis in WHHL rabbits. Atherosclerosis 166: 1321.
  • Brennan ML, Penn MS, Van Lente F, Nambi V, Shishehbor MH, Aviles RJ et al. (2003). Prognostic value of myeloperoxidase in patients with chest pain. N Engl J Med 349: 15951604.
  • Burner U, Krapfenbauer G, Furtmüller PG, Regelsberger G, Obinger C (2000). Oxidation of hydroquinone, 2,3-dimethylhydroquinone and 2,3,5-trimethylhydroquinone by human myeloperoxidase. Redox Rep 5: 185190.
  • Burner U, Obinger C, Paumann M, Furtmüller PG, Kettle AJ (1999). Transient and steady-state kinetics of the oxidation of substituted benzoic acid hydrazides by myeloperoxidase. J Biol Chem 274: 94949502.
  • Buss IH, Senthilmohan R, Darlow BA, Mogridge N, Kettle AJ, Winterbourn CC (2003). 3-Chlorotyrosine as a marker of protein damage by myeloperoxidase in tracheal aspirates from preterm infants: association with adverse respiratory outcome. Pediatr Res 53: 455462.
  • Carr AC, Tijerina T, Frei B (2000). Vitamin C protects against and reverses specific hypochlorous acid- and chloramine-dependent modifications of low-density lipoprotein. Biochem J 346: 491499.
  • Castellani LW, Chang JJ, Wang X, Lusis AJ, Reynolds WF (2006). Transgenic mice express human MPO −463G/A alleles at atherosclerotic lesions, developing hyperlipidemia and obesity in −463G males. J Lipid Res 47: 13661377.
  • Chesney JA, Mahoney JR, Eaton JW (1991). A spectrophotometric assay for chlorine-containing compounds. Anal Biochem 196: 262266.
  • Cho Y, Jang YY, Han ES, Lee CS (1999). The inhibitory effect of ambroxol on hypochlorous acid-induced tissue damage and respiratory burst of phagocytic cells. Eur J Pharmacol 383: 8391.
  • Choi DK, Pennathur S, Perier C, Tieu K, Teismann P, Wu DC et al. (2005). Ablation of the inflammatory enzyme myeloperoxidase mitigates features of Parkinson's disease in mice. J Neurosci 25: 65946600.
  • Cuperus RA, Muijsers AO, Wever R (1983). The effect of D-penicillamine on human myeloperoxidase: a mechanism for the efficacy of the drug in rheumatoid arthritis. Biochim Biophys Acta 749: 1823.
  • Cuperus RA, Muijsers AO, Wever R (1985). Antiarthritic drugs containg thiol groups scavenge hypochlorite and inhibit its formation by myeloperoxidase from human leukocytes. Arthritis Rheum 28: 12281233.
  • Daugherty A, Rateri DL, Dunn JL, Heinecke JW (1994). Myeloperoxidase, a catalyst for lipoprotein oxidation, is expressed in human atherosclerotic lesions. J Clin Invest 94: 437444.
  • Davey CA, Fenna RE (1996). 2.3 Å resolution X-ray crystal structure of the bisubstrate analogue inhibitor salicylhydroxamic acid bound to human myeloperoxidase: a model for a prereaction complex with hydrogen peroxide. Biochemistry 35: 1096710973.
  • Davies B, Edwards SW (1989). Inhibition of myeloperoxidase by salicylhydroxamic acid. Biochem J 258: 801806.
  • Dolphin D, Forman A, Borg DC, Fajer J, Felton RH (1971). Compounds I of catalase and horseradish peroxidase: p-cation radicals. Proc Natl Acad Sci USA 68: 614618.
  • Dunford HB (1999). Myeloperoxidase and eosinophil peroxidase: phagocytosis and microbial killing. In: Dunford HB (ed). Heme Peroxidases. Wiley-VCH: New York, pp 349385.
  • Dypbukt JM, Bishop C, Brooks WM, Thong B, Eriksson H, Kettle AJ (2005). A sensitive and selective assay for chloramine production by myeloperoxidase. Free Radic Biol Med 39: 14681477.
  • Eiserich JP, Baldus S, Brennan ML, Ma W, Zhang C, Tousson A et al. (2002). Myeloperoxidase, a leukocyte-derived vascular NO oxidase. Science 296: 23912394.
  • Fiedler TJ, Davey CA, Fenna RE (2000). X-ray crystal structure and characterization of halide-binding sites of human myeloperoxidase at 1.8 Å resolution. J Biol Chem 275: 1196411971.
  • Furst SM, Uetrecht JP (1993). Carbamazepin metabolism to a reactive intermediate by the myeloperoxidase system of activated neutrophils. Biochem Pharmacol 45: 12671275.
  • Furtmüller PG, Arnhold J, Jantschko W, Pichler H, Obinger C (2003). Redox properties of the couples compound I/compound II and compound II/native enzyme of human myeloperoxidase. Biochem Biophys Res Commun 301: 551557.
  • Furtmüller PG, Burner U, Obinger C (1998). Reaction of human myeloperoxidase compound I with chloride, bromide, iodide, and thiocyanate. Biochemistry 37: 1792317930.
  • Furtmüller PG, Jantschko W, Regelsberger G, Jakopitsch C, Moguilevsky N, Obinger C (2001). A transient kinetic study on the reactivity of recombinant unprocessed monomeric myeloperoxidase. FEBS Lett 503: 147150.
  • Furtmüller PG, Zederbauer M, Jantschko W, Helm J, Bogner M, Jakopitsch C et al. (2006). Active site structure and catalytic mechanisms of human peroxidases. Arch Biochem Biophys 445: 199213.
  • Gröne HJ, Gröne EF, Malle E (2002). Immunohistochemical detection of hypochlorite-modified proteins in glomeruli of human membranous glomerulonephritis. Lab Invest 82: 514.
  • Gujral JS, Liu J, Farhood A, Hinson JA, Jaeschke H (2004). Functional importance of ICAM-1 in the mechanism of neutrophil-induced liver injury in bile duct-ligated mice. Am J Physiol Gastrointest Liver Physiol 286: G499G507.
  • Hallingbäck HR, Gabdoulline RR, Wade RC (2006). Comparison of the binding and reactivity of plant and mammalian peroxidases to indole derivatives by computational docking. Biochemistry 45: 29402950.
  • Hampton MB, Kettle AJ, Winterbourn CC (1998). Inside the neutrophil phagosome: oxidants, myeloperoxidase, and bacterial killing. Blood 92: 30073017.
  • Hansch C, Leo A (1979). Substituent Constants for Correlation Analysis in Chemistry and Biology. John Wiley & Sons, Inc.: New York.
  • Hansson M, Olsson I, Nauseef WM (2006). Biosynthesis, processing, and sorting of human myeloperoxidase. Arch Biochem Biophys 445: 214224.
  • Hasegawa T, Malle E, Farhood A, Jaeschke H (2005). Generation of hypochlorite-modified proteins by neutrophils during ischemia-reperfusion injury in rat liver: attenuation by ischemic preconditioning. Am J Physiol Gastrointest Liver Physiol 289: G760G767.
  • Hawkins CL, Davies MJ (1998). Hypochlorite-induced damage to proteins: formation of nitrogen-centred radicals from lysine residues and their role in protein fragmentation. Biochem J 332: 617625.
  • Hazell LJ, Arnold L, Flowers D, Waeg G, Malle E, Stocker R (1996). Presence of hypochlorite-modified proteins in human atherosclerotic lesions. J Clin Invest 97: 15351544.
  • Hazen SL, Heinecke JW (1997). 3-Chlorotyrosine, a specific marker of myeloperoxidase-catalyzed oxidation, is markedly elevated in low density lipoprotein isolated from human atherosclerotic intima. J Clin Invest 99: 20752081.
  • Hazen SL, Hsu FF, Mueller DM, Crowley JR, Heinecke JW (1996). Human neutrophils employ chlorine gas as an oxidant during phagocytosis. J Clin Invest 98: 12831289.
  • Hori H, Fenna RE, Kimura S, Ikeda-Saito M (1994). Aromatic substrate molecules bind at the distal heme pocket of myeloperoxidase. J Biol Chem 269: 83888392.
  • Hoy A, Trégouet D, Leininger-Muller B, Poirier O, Maurice M, Sass C et al. (2001). Serum myeloperoxidase concentration in a healthy population: biological variations, familial resemblance and new genetic polymorphisms. Eur J Hum Genet 9: 780786.
  • Hsuanyu Y, Dunford HB (1999). Oxidation of clozapine and ascorbate by myeloperoxidase. Arch Biochem Biophys 368: 413420.
  • Ikeda-Saito M, Shelley DA, Lu L, Booth KS, Caughey WS, Kimura S (1991). Salicylhydroxamic acid inhibits myeloperoxidase activity. J Biol Chem 266: 36113616.
  • Jacquet A, Deby C, Mathy M, Moguilevsky N, Deby-Dupont G, Thirion A et al. (1991). Spectral and enzymatic properties of human recombinant myeloperoxidase: comparison with the mature enzyme. Arch Biochem Biophys 291: 132138.
  • Jantschko W, Furtmüller PG, Allegra M, Livrea MA, Jakopitsch C, Regelsberger G et al. (2002). Redox intermediates of plant and mammalian peroxidases: a comparative transient-state kinetic study of their reactivity toward indole derivatives. Arch Biochem Biophys 398: 1222.
  • Jantschko W, Furtmüller PG, Zederbauer M, Neugschwandtner K, Lehner I, Jakopitsch C et al. (2005). Exploitation of the unusual properties of human myeloperoxidase in inhibitor design. Biochem Pharmacol 69: 11491157.
  • Josephy PD, Eling T, Mason RP (1982). The horseradish peroxidase-catalyzed oxidation of 3,5,3′,5′-tetramethylbenzidine. Free radical and charge-transfer complex intermediates. J Biol Chem 257: 36693675.
  • Kettle AJ, Candaeis LP (2000). Oxidation of tryptophan by redox intermediates of myeloperoxidase and inhibition of hypochlorous acid production. Redox Rep 5: 179184.
  • Kettle AJ, Chan T, Osberg I, Senthilmohan R, Chapman AL, Mocatta TJ et al. (2004). Myeloperoxidase and protein oxidation in the airways of young children with cystic fibrosis. Am J Respir Crit Care Med 170: 13171323.
  • Kettle AJ, Gedye CA, Hampton MB, Winterbourn CC (1995). Inhibition of myeloperoxidase by benzoic acid hydrazides. Biochem J 308: 559563.
  • Kettle AJ, Gedye CA, Winterbourn CC (1993). Superoxide is an antagonist of anti-inflammatory drugs that inhibit hypochlorous acid production by myeloperoxidase. Biochem Pharmacol 45: 20032010.
  • Kettle AJ, Gedye CA, Winterbourn CC (1997). Mechanism of inactivation of myeloperoxidase by 4-aminobenzoic acid hydrazide. Biochem J 321: 503508.
  • Kettle AJ, Robertson IG, Palmer BD, Anderson RF, Patel KB, Winterbourn CC (1992). Oxidative metabolism of amsacrine by the neutrophil enzyme myeloperoxidase. Biochem Pharmacol 44: 17311738.
  • Kettle AJ, Winterbourn CC (1988). The mechanism of myeloperoxidase-dependent chlorination of monochlorodimedon. Biochim Biophys Acta 957: 185191.
  • Kettle AJ, Winterbourn CC (1991). Mechanism of inhibition of myeloperoxidase by anti-inflammatory drugs. Biochem Pharmacol 41: 14851492.
  • Kettle AJ, Winterbourn CC (1992). Oxidation of hydroquinone by myeloperoxidase. Mechanism of stimulation by benzoquinone. J Biol Chem 267: 83198324.
  • Kettle AJ, Winterbourn CC (1994). Assays for the chlorination activity of myeloperoxidase. Methods Enzymol 233: 502512.
  • Klebanoff SJ (2005). Myeloperoxidase: friend and foe. J Leukoc Biol 77: 598625.
  • Klebanoff SJ, Waltersdorph AM (1988). Inhibition of peroxidase-catalyzed reactions by desferoxamine. Arch Biochem Biophys 264: 600606.
  • Koeffler HP, Ranyard J, Pertcheck M (1985). Myeloperoxidase: its structure and expression during myeloid differentiation. Blood 65: 484491.
  • Kono Y, Shibata H, Kodama Y, Ueda A, Sawa Y (1995). Chlorogenic acid as a natural scavenger for hypochlorous acid. Biochem Biophys Res Commun 217: 972978.
  • Kooter IM, Moguilevsky N, Bollen A, Sijtsema NM, Otto C, Wever R (1997). Site-directed mutagenesis of Met243, a residue of myeloperoxidase involved in binding of the prosthetic group. J Biol Inorg Chem 2: 191197.
  • Kubow S, Wells PG (1989). In vitro bioactivation of phenytoin to a reactive free radical intermediate by prostaglandin synthetase, horseradisch peroxidase, and thyroid peroxidase. Mol Pharmacol 35: 504511.
  • Kumar AP, Reynolds WF (2005). Statins downregulate myeloperoxidase gene expression in macrophages. Biochem Biophys Res Commun 331: 442451.
  • Kutter D, Devaquet P, Vanderstocken G, Paulus JM, Marchal V, Gothot A (2000). Consequences of total and subtotal myeloperoxidase deficiency: risk or benefit Acta Haematol 104: 1015.
  • Lai WG, Gardner I, Zahid N, Uetrecht JP (2000). Bioactivation and covalent binding of hydroxyfluperlapine in human neutrophils: implications for fluperlapine-induced agranulocytosis. Drug Metab Dispos 28: 255263.
  • Lai WG, Zahid N, Uetrecht JP (1999). Metabolism of trimethoprim to a reactive iminoquinone methide by activated human neutrophils and hepatic microsomes. J Pharmacol Exp Ther 291: 292299.
  • Leßig J, Schiller J, Arnhold J, Fuchs B (2007). Hypochlorous acid-mediated generation of glycerophosphocholine from unsaturated plasmalogen glycerophosphocholine lipids. J Lipid Res 48: 13161324.
  • Lee E, Miki Y, Katsura H, Kariya K (1990). Mechanism of inactivation of myeloperoxidase by propylthiouracil. Biochem Pharmacol 39: 14671471.
  • Lewis D, Capell HA, McNeil CJ, Iqbal MS, Brown DH, Smith WE (1983). Gold levels produced by treatment with auranofin and sodium-aurothiomalate. Ann Rheum Dis 42: 566570.
  • Maehly AC, Chance B (1954). The assay of catalases and peroxidases. Methods Biochem Anal 1: 357424.
  • Malle E, Buch T, Grone HJ (2003). Myeloperoxidase in kidney disease. Kidney Int 64: 19561967.
  • Malle E, Hazell L, Stocker R, Sattler W, Esterbauer H, Waeg G (1995). Immunologic detection and measurement of hypochlorite-modified LDL with specific monoclonal antibodies. Arterioscler Thromb Vasc Biol 15: 982989.
  • Malle E, Marsche G, Arnhold J, Davies MJ (2006a). Modification of low-density lipoprotein by myeloperoxidase-derived oxidants and reagent hypochlorous acid. Biochim Biophys Acta 1761: 392415.
  • Malle E, Marsche G, Panzenboeck U, Sattler W (2006b). Myeloperoxidase-mediated oxidation of high-density lipoproteins: fingerprints of newly recognized potential proatherogenic lipoproteins. Arch Biochem Biophys 445: 245255.
  • Malle E, Waeg G, Schreiber R, Gröne EF, Sattler W, Gröne HJ (2000). Immunohistochemical evidence for the myeloperoxidase/H2O2/halide system in human atherosclerotic lesions. Eur J Biochem 267: 44954503.
  • Malle E, Wäg G, Thiery J, Sattler W, Gröne HJ (2001). Hypochlorite-modified (lipo)proteins are present in rabbit lesions in response to dietary cholesterol. Biochem Biophys Res Commun 289: 894900.
  • Malle E, Woenckhaus C, Waeg G, Esterbauer H, Grone EF, Grone HJ (1997). Immunological evidence for hypochlorite-modified proteins in human kidney. Am J Pathol 150: 603615.
  • Marquez LA, Dunford HB (1995). Kinetics of oxidation of tyrosine and dityrosine by myelo-peroxidase compounds I and II. Implications for lipoprotein peroxidation studies. J Biol Chem 270: 3043430440.
  • Marquez LA, Dunford HB (1997). Mechanism of the oxidation of 3,5,3′,5′-tetramethylbenzidine by myeloperoxidase determined by transient- and steady-state kinetics. Biochemistry 36: 93499355.
  • Marquez LA, Dunford HB, Van Wart H (1990). Kinetic studies on the reaction of compound II of myeloperoxidase with ascorbic acid. Role of ascorbic acid in myeloperoxidase function. J Biol Chem 265: 566656670.
  • Marsche G, Heller R, Fauler G, Kovacevic A, Nuszkowski A, Graier W et al. (2004). 2-Chlorohexadecanal derived from hypochlorite-modified high-density lipoprotein-associated plasmalogen is a natural inhibitor of endothelial nitric oxide biosynthesis. Arterioscler Thromb Vasc Biol 24: 23022306.
  • Marsche G, Levak-Frank S, Quehenberger O, Heller R, Sattler W, Malle E (2001). Identification of the human analog of SR-BI and LOX-1 as receptors for hypochlorite-modified high density lipoprotein on human umbilical venous endothelial cells. FASEB J 15: 10951097.
  • Marsche G, Semlitsch M, Hammer A, Frank S, Weigle B, Demling N et al. (2007a). Hypochlorite-modified albumin colocalizes with RAGE in the artery wall and promotes MCP-1 expression via the RAGE-Erk1/2 MAP-kinase pathway. FASEB J 21: 11451152.
  • Marsche G, Weigle B, Sattler W, Malle E (2007b). Soluble RAGE blocks scavenger receptor CD-36-mediated uptake of hypochlorite-modified low-density lipoprotein. FASEB J 21 (in press). Doi:DOI: 10.1096/fj.07-8316com.
  • Marsche G, Zimmermann R, Horiuchi S, Tandon NN, Sattler W, Malle E (2003). Class B scavenger receptors CD36 and SR-BI are receptors for hypochlorite-modified low density lipoprotein. J Biol Chem 278: 4756247570.
  • Mays DC, Pawluk LJ, Apseloff G, Davis WB, She ZW, Sagone AL et al. (1995). Metabolism of phenytoin and covalent binding of reactive intermediates in activated human neutrophils. Biochem Pharmacol 50: 367380.
  • McCarty MF (1999). The reported clinical utility of taurine in ischemic disorders may reflect a down-regulation of neutrophil activation and adhesion. Med Hypotheses 53: 290299.
  • McGirr LG, Jatoe SD, O'Brien PJ (1990). Myeloperoxidase catalysed cooxidative metabolism of methimazole: oxidation of glutathione and NADH by free radical intermediates. Chem Biol Interact 73: 279295.
  • McMillen TS, Heinecke JW, LeBoeuf RC (2005). Expression of human myeloperoxidase by macrophages promotes atherosclerosis in mice. Circulation 111: 27982804.
  • Milla C, Yang S, Cornfield DN, Brennan ML, Hazen SL, Panoskaltsis-Mortari A et al. (2004). Myeloperoxidase deficiency enhances inflammation after allogeneic marrow transplantation. Am J Physiol Lung Cell Mol Physiol 287: L706L714.
  • Misra HP, Fridovich I (1976). The oxidation of phenylhydrazine: superoxide and mechanism. Biochemistry 10: 681687.
  • Miyamoto G, Zahid N, Uetrecht JP (1997). Oxidation of diclofenac to reactive intermediates by neutrophils, myeloperoxidase, and hypochlorous acid. Chem Res Toxicol 10: 414419.
  • Miyamoto S, Martinez GR, Rettori D, Augusto O, Medeiros MH, Di Mascio P (2006). Linoleic acid hydroperoxide reacts with hypochlorous acid, generating peroxyl radical intermediates and singlet molecular oxygen. Proc Natl Acad Sci USA 103: 293298.
  • Moguilevsky N, Garcia-Quintana L, Jacquet A, Tournay C, Fabry L, Pierard L et al. (1991). Structural and biological properties of human recombinant myeloperoxidase produced by Chinese hamster ovary cell lines. Eur J Biochem 197: 605614.
  • Murakami S, Kondo Y, Sakurai T, Kitajima H, Nagate T (2002). Taurine suppresses development of atherosclerosis in Watanabe heritable hyperlipidemic (WHHL) rabbits. Atherosclerosis 163: 7987.
  • Murakami S, Kondo Y, Tomisawa K, Nagate T (1999a). Prevention of atherosclerotic lesion development in mice by taurine. Drugs Exp Clin Res 25: 227234.
  • Murakami S, Kondo-Ohta Y, Tomisawa K (1999b). Improvement in cholesterol metabolism in mice given chronic treatment of taurine and fed a high-fat diet. Life Sci 64: 8391.
  • Nakano M, Koga S (1994). Luciferin derivative for assay of myeloperoxidase and dopamine metabolism. Methods Enzymol 233: 495501.
  • Nappi AJ, Vass E (2001). The effects of nitric oxide on the oxidations of L-dopa and dopamine mediated by tyrosinase and peroxidase. J Biol Chem 276: 1121411222.
  • Nauseef WM, Cogley M, Bock S, Petrides PE (1998). Pattern of inheritance in hereditary myeloperoxidase deficiency associated with the R569W missense mutation. J Leukoc Biol 63: 264269.
  • Neve J, Parij N, Moguilevsky N (2001). Inhibition of the myeloperoxidase chlorinating activity by non-steroidal anti-inflammatory drugs investigated with a human recombinant enzyme. Eur J Pharmacol 417: 3743.
  • Nicholls SJ, Hazen SL (2005). Myeloperoxidase and cardiovascular disease. Arterioscler Thromb Vasc Biol 25: 11021111.
  • Panasenko OM, Arnhold J, Vladimirov YuA, Arnhold K, Sergienko VI (1997). Hypochlorite-induced peroxidation of egg yolk phosphatidylcholine is mediated by hydroperoxides. Free Radic Res 27: 112.
  • Petty MA, Kintz J, DiFrancesco GF (1990). The effects of taurine on atherosclerosis development in cholesterol-fed rabbits. Eur J Pharmacol 180: 119127.
  • Proteasa G, Tahboub YR, Galijasevic S, Raushel FM, Abu-Soud HM (2007). Kinetic evidence supports the existence of two halide binding sites that have a distinct impact on the heme iron microenvironment in myeloperoxidase. Biochemistry 46: 398405.
  • Reynolds WF, Kumar AP, Piedrafita FJ (2006). The human myeloperoxidase gene is regulated by LXR and PPARα ligands. Biochem Biophys Res Commun 349: 846854.
  • Rider NL, Pinto D, Covington M, Orwat MJ, Giannaras J, Nurnberg S et al. (1996). Comparative effects of selective cyclooxygenase 1 and cyclooxygenase 2 inhibitors on myeloperoxidase and 3α-hydroxysteroid dehydrogenase. J Enzyme Inhib 10: 7379.
  • Roy G, Mugesh G (2005). Anti-thyroid drugs and thyroid hormone synthesis: effect of methimazole derivatives on peroxidase-catalyzed reactions. J Am Chem Soc 127: 1520715217.
  • Sagone AL, Husney RM, Wevers MD, Herzyk DJ, Davis WB (1989). Effect of dimethylthiourea on the neutrophil myeloperoxidase pathway. J Appl Physiol 67: 10561062.
  • Sayo H, Saito M (1991). Hydrogen peroxide-dependent oxidation metabolism of 1-methyl-2-mercaptoimidazole (methimazole) catalysed by myeloperoxidase. Xenobiotica 21: 12171224.
  • Scheuer H, Gwinner W, Hohbach J, Gröne EF, Brandes RP, Malle E et al. (2000). Oxidant stress in hyperlipidemia-induced renal damage. Am J Physiol Renal Physiol 278: F63F74.
  • Schonbaum GR (1973). New complexes of peroxidases with hydroxamic acids, hydrazides, and amides. J Biol Chem 248: 502511.
  • Schonbaum GR, Lo S (1972). Interaction of peroxidases with aromatic peracids and alkyl peroxides. J Biol Chem 247: 33533360.
  • Schuller-Levis GB, Park E (2003). Taurine: new implications for an old amino acid. FEMS Microbiol Lett 226: 195202.
  • Schultz J, Kaminker K (1962). Myeloperoxidase of the leucocyte of normal human blood. I. Content and localization. Arch Biochem Biophys 96: 465467.
  • Shacter E, Lopez RL, Pati S (1991). Inhibition of the myeloperoxidase-H2O2-Clsystem of neutrophils by indomethacin and other non-steroidal anti-inflammatory drugs. Biochem Pharmacol 41: 975984.
  • Soyer Z, Bas M, Pabuccuoglu A, Pabuccuoglu V (2005). Synthesis of some 2(3H)-benzoxazolone derivatives and their in-vitro effects on human leukocyte myeloperoxidase activity. Arch Pharm Chem Life Sci 338: 405410.
  • Stendahl O, Molin L, Dahlgren C (1978). The inhibition of polymorphonuclear leukocyte cytotoxicity by dapsone: a possible mechanism in the treatment of dermatitis herpetiformis. J Clin Invest 62: 214220.
  • Stenvinkel P, Rodríguez-Ayala E, Massy ZA, Qureshi AR, Barany P, Fellström B et al. (2006). Strain treatment and diabetes affect myeloperoxidase activity in maintenance hemodialysis patients. Clin J Am Soc Nephrol 1: 281287.
  • Suzuki K, Ota H, Sasagawa S, Sakatani T, Fujikura T (1983). Assay method for myeloperoxidase in human polymorphonuclear leukocytes. Anal Biochem 132: 345352.
  • Takeshita J, Byun J, Nhan TQ, Pritchard DK, Pennathur S, Schwartz SM et al. (2006). Myeloperoxidase generates 5-chlorouracil in human atherosclerotic tissue: a potential pathway for somatic mutagenesis by macrophages. J Biol Chem 281: 30963104.
  • Tarpey MM, Wink DA, Grisham MB (2004). Methods for detection of reactive metabolites of oxygen and nitrogen: in vitro and in vivo considerations. Am J Physiol Regul Integr Comp Physiol 286: R431R444.
  • Thomas EL, Grisham MB, Jefferson MM (1986). Preparation and characterization of chloramines. Methods Enzymol 132: 569585.
  • Thukkani AK, Martinson BD, Albert CJ, Vogler GA, Ford DA (2005). Neutrophil-mediated accumulation of 2-ClHDA during myocardial infarction: 2-ClHDA-mediated myocardial injury. Am J Physiol Heart Circ Physiol 288: H2955H2964.
  • Thukkani AK, McHowat J, Hsu FF, Brennan ML, Hazen SL, Ford DA (2003). Identification of alpha-chloro fatty aldehydes and unsaturated lysophosphatidylcholine molecular species in human atherosclerotic lesions. Circulation 108: 31283133.
  • Uetrecht J, Zahid N (1988). N-chlorination of phenytoin by myeloperoxidase to a reactive metabolite. Chem Res Toxicol 1: 148151.
  • Uetrecht J, Zahid N, Tehim A, Fu JM, Rakhit S (1997). Structural features associated with reactive metabolite formation in clozapine analogues. Chem Biol Interact 104: 117129.
  • Uetrecht JP, Zahid N (1991). N-Chlorination and oxidation of procainamide by myeloperoxidase: toxicological implications. Chem Res Toxicol 4: 218222.
  • Van der Korst JK, van de Stadt RJ, Muijsers AO, Ament HJ, Henrichs AM (1981). Pharmacokinetics of D-penicillamine in rheumatoid arthritis. In: Maini RN, Berry H (eds). Modulation of Autoimmunity and Disease. Praeger: New York, pp 165171.
  • van Zyl JM, Basson K, Kriegler A, van der Walt BJ (1990). Activation of chlorpromazine by the myeloperoxidase system of the human neutrophil. Biochem Pharmacol 40: 947954.
  • van Zyl JM, Basson K, Uebel RA, van der Walt BJ (1989a). Isoniazid-mediated irreversible inhibition of the myeloperoxidase antimicrobial system of the human neutrophil and the effect of thyronines. Biochem Pharmacol 38: 23632373.
  • van Zyl JM, Basson K, van der Walt BJ (1989b). The inhibitory effect of acetaminophen on the myeloperoxidase-induced antimicrobial system of the polymorphonuclear leukocyte. Biochem Pharmacol 38: 161165.
  • Van Zyl JM, van der Walt BJ (1996). Thiacetazone acts as a scavenger of myeloperoxidase-generated hypochlorous acid and singlet oxygen. Med Sci Res 24: 181183.
  • Weiss SJ, Klein R, Slivka A, Wei M (1982). Chlorination of taurine by human neutrophils. Evidence for hypochlorous acid generation. J Clin Invest 70: 598607.
  • Williams DP, Pirmohamed M, Naisbitt DJ, Maggs JL, Park BK (1997). Neutrophil cytotoxicity of the chemically reactive metabolite(s) of clozapine: possible role in agranolocytosis. J Pharmacol Exp Ther 283: 13751382.
  • Wolber G, Langer T (2005). LigandScout: 3-D pharmacophores derived from protein-bound ligands and their use as virtual screening filters. J Chem Inf Model 45: 160169.
  • Yamada M, Kurahashi K (1984). Regulation of myeloperoxidase gene expression during differentiation of human myeloid leukemia HL-60 cells. J Biol Chem 259: 30213025.
  • Yang X-X, Hu Z-P, Chan SY, Zhou SF (2006). Monitoring drug–protein interaction. Clin Chim Acta 365: 929.
  • Zederbauer M, Furtmüller PG, Bellei M, Stampler J, Jakopitsch C, Battistuzzi G et al. (2007a). Disruption of the aspartate to heme ester linkage in human myeloperoxidase: impact on ligand binding, redox chemistry and interconversion of redox intermediates. J Biol Chem 282: 1704117052.
  • Zederbauer M, Furtmüller PG, Ganster B, Moguilevsky N, Obinger C (2007b). Manipulating the vinyl-sulfonium bond in human myeloperoxidase: impact on compound I formation and reduction by halides and thiocyanate. Biochem Biophys Res Commun 356: 450456.
  • Zederbauer M, Jantschko W, Neugschwandtner K, Jakopitsch C, Moguilevsky N, Obinger C et al. (2005). The role of the covalent Glu242-heme linkage in the formation and reactivity of redox intermediates of human myeloperoxidase. Biochemistry 44: 64826491.
  • Zeng J, Fenna RE (1992). X-ray crystal structure of canine myeloperoxidase at 3 Å resolution. J Mol Biol 226: 185207.
  • Zheng L, Nukuna B, Brennan ML, Sun M, Goormastic M, Settle M et al. (2004). Apolipoprotein A-I is a selective target for myeloperoxidase-catalyzed oxidation and functional impairment in subjects with cardiovascular disease. J Clin Invest 114: 529541.
  • Zhou T, Zhou SH, Qi SS, Shen XQ, Zeng GF, Zhou HN (2006). The effect of atorvastatin on serum myeloperoxidase and CRP levels in patients with acute coronary syndrome. Clin Chim Acta 368: 168172.
  • Zhu BZ, Carr AC, Frei B (2002). Pyrrolidine dithiocarbamate is a potent antioxidant against hypochlorous acid-induced protein damage. FEBS Lett 532: 8084.
  • Zuurbier KWM, Bakkenist ARJ, Fokkens RH, Nibbering NMM, Wever R, Muijsers AO (1990). Inhibition of the chlorinating activity of myeloperoxidase by diclofenac and oxidation of diclofenac to dihydroxyazobenzene by myeloperoxidase. Biochem Pharmacol 40: 18011808.